Tenders Are Invited For Pituitary, Hypothalamic Hormones And Analogues – Preparation Of Recombinant Human Insulin-Like Growth Factor - 1 (Mecasermin) For Administration In Generally Available Syringes Of Low Capacity And High Precision: - Vial/Ampoule With A Capacity Of < 50 Mg; Reference Number: Zzp.Zp.411.83.2026

Pituitary, Hypothalamic Hormones And Analogues – Preparation Of Recombinant Human Insulin-Like Growth Factor - 1 (Mecasermin) For Administration In Generally Available Syringes Of Low Capacity And High Precision: - Vial/Ampoule With A Capacity Of < 50 Mg; Reference Number: Zzp.Zp.411.83.2026. 1.The Total Size Of The Basic Order Is: 135,330 Mg. 2. The Ordering Party Reserves The Right To Increase The Quantity Of The Subject Of The Order, But Not More Than 15% Of The Basic Order, In An Amount Of 20,250 Mg. 3. The Ordering Party Anticipates Changing The Size Of The Subject Of The Order During The Term Of The Contract, I.E. It Is Possible To Reduce The Ordered Volume - By 20% Of The Size Of The Basic Order, In The Event Of Objective And Justified Needs, In Particular Changes In Demand Among Patients - This Change Depends On The Internal Needs Of Direct Recipients, Which May Appear During The Execution Of The Order And Is Left Solely To The Ordering Partys Decision. When Submitting An Offer, The Contractor Acknowledges The Possibility Of Various Circumstances Affecting Changes In Demand. 4. The Offered Drug Is Registered And Reimbursed For The Treatment Of Patients With Short Stature Due To Severe Primary Igf-1 Deficiency With Recombinant Igf-1. 5. The Offered Preparation Must Meet The Conditions Of Use In The Above-Mentioned. Indication For Patients Covered By Drug Program B.20, Treatment Of Short-Statured Children With Severe Primary Insulin-Like Growth Factor 1 Deficiency With Recombinant Human Insulin-Like Growth Factor-1. 6. Pursuant To Art. 255 Point 3 Of The Public Procurement Act, The Ordering Party May Invalidate The Public Procurement Procedure If The Price Or Cost Of The Most Advantageous Offer Or The Offer With The Lowest Price For The Basic Contract Exceeds The Amount That The Ordering Party Intends To Allocate To Finance The Contract. 7. Pursuant To Art. 256 Of The Public Procurement Act, The Ordering Party May Invalidate The Contract Award Procedure Appropriately Before The Deadline For Submitting Offers If There Are Circumstances That Make Further Conduct Of The Procedure Unjustified. 8. Pursuant To Art. 257 Of The Public Procurement Law. The Contracting Authority Provides For The Possibility Of Invalidating The Public Procurement Procedure If The Funds It Intended To Allocate To Finance All Or Part Of The Contract Were Not Granted. 9. The Order Must Be Completed In Accordance With The Requirements Specified In The Swz And In The Draft Provisions Of The Agreement. A Detailed Description Of The Subject Of The Order Is Specified In The Terms Of Reference (Swz). Means Of Evidence: Pursuant To Art. 105 And Art. 106 Pzp. In Order To Confirm Compliance Of The Offered Supplies With The Requirements, Features Or Criteria Specified In The Description Of The Subject Of The Order Or The Offer Evaluation Criteria Or Requirements Related To The Implementation Of The Order, The Ordering Party Requests The Contractors To Present The Following Documents: • A Valid Marketing Authorization For A Medicinal Product In The Territory Of The Republic Of Poland Issued By The President Of The Office For Registration Of Medicinal Products, Medical Devices And Biocidal Products, Or • A Valid Marketing Authorization For A Medicinal Product Issued By The Council Of The European Union Or The European Commission. 2.2. In Case